Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium lactis HN001
- Development stage
- Unknown
- Lead developer
- Fonterra
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bifidobacterium lactis* HN001 is a specific probiotic bacterial strain originally isolated from a yogurt source and classified within the *Bifidobacterium animalis* subsp. *lactis* group. It is widely utilized in dietary supplements and functional foods, particularly for its immunomodulatory properties. Clinical research has demonstrated its potential to reduce the risk of atopic dermatitis (eczema) and allergic sensitization in infants when administered to mothers during pregnancy and to infants during early life. The strain is thought to work by modulating the gut microbiota and interacting with the host immune system to promote a balanced Th1/Th2 response and enhance intestinal barrier function. In addition to allergy prevention, it has been investigated for its role in gut health, metabolic function, and mental well-being. The strain was originally developed by Fonterra and is currently commercialized as part of the HOWARU probiotic range by IFF (formerly DuPont/Danisco).
- Brand names
- HOWARU Premium ProbioticsHOWARU Protect EarlyLife
- Other names
- Bifidobacterium animalis subsp. lactis HN001Bifidobacterium animalis HN001
Beyond the preview
Go deeper on Bifidobacterium lactis HN001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium lactis HN001.